Cell therapy in Parkinson’s disease Authors
Cite this article as: Lindvall, O. & Björklund, A. Neurotherapeutics (2004) 1: 382. doi:10.1602/neurorx.1.4.382 Summary
The clinical studies with intrastriatal transplants of fetal mesencephalic tissue in Parkinson’s disease (PD) patients have provided proof-of-principle for the cell replacement strategy in this disorder. The grafted dopaminergic neurons can reinnervate the denervated striatum, restore regulated dopamine (DA) release and movement-related frontal cortical activation, and give rise to significant symptomatic relief. In the most successful cases, patients have been able to withdraw
l-dopa treatment after transplantation and resume an independent life. However, there are currently several problems linked to the use of fetal tissue: 1) lack of sufficient amounts of tissue for transplantation in a large number of patients, 2) variability of functional outcome with some patients showing major improvement and others modest if any clinical benefit, and 3) occurrence of troublesome dyskinesias in a significant proportion of patients after transplantation. Thus, neural transplantation is still at an experimental stage in PD. For the development of a clinically useful cell therapy, we need to define better criteria for patient selection and how graft placement should be optimized in each patient. We also need to explore in more detail the importance for functional outcome of the dissection and cellular composition of the graft tissue as well as of immunological mechanisms. Strategies to prevent the development of dyskinesias after grafting have to be developed. Finally, we need to generate large numbers of viable DA neurons in preparations that are standardized and quality controlled. The stem cell technology may provide a virtually unlimited source of DA neurons, but several scientific issues need to be addressed before stem cell-based therapies can be tested in PD patients. Key Words Parkinson’s disease transplantation stem cells neural grafts dopamine Download to read the full article text References
Lindvall O, Brundin P, Widner H, Rehncrona S, Gustavii B, Frackowiak R et al. Grafts of fetal dopamine neurons survive and improve motor function in Parkinson’s disease.
247: 574–577, 1990.
Lindvall O, Widner H, Rehncrona S, Brundin P, Odin P, Gustavii B et al. Transplantation of fetal dopamine neurons in Parkinson’s disease: one-year clinical and neurophysiological observations in two patients with putaminal implants.
31: 155–165, 1992.
Lindvall O, Sawle G, Widner H, Rothwell JC, Bjorklund A, Brooks D et al. Evidence for long-term survival and function of dopaminergic grafts in progressive Parkinson’s disease.
35: 172–180, 1994.
Sawle GV, Bloomfield PM, Bjorklund A, Brooks DJ, Brundin P, Leenders, KL et al. Transplantation of fetal dopamine neurons in Parkinson’s disease: PET [18F]6-
-fluorodopa studies in two patients with putaminal implants.
31: 166–173, 1992.
Widner H, Tetrud J, Rehncrona S, Snow B, Brundin P, Gustavii B et al. Bilateral fetal mesencephalic grafting in two patients with parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP).
N Engl J Med
327: 1556–1563, 1992.
Peschanski M, Defer G, N’Guyen JP, Ricolfi F, Monfort JC, Remy P et al. Bilateral motor improvement and alteration of
-dopa effect in two patients with Parkinson’s disease following intrastriatal transplantation of foetal ventral mesencephalon.
117: 487–499, 1994.
Freeman TB, Olanow CW, Hauser RA, Nauert GM, Smith DA, Borlongan CV et al. Bilateral fetal nigral transplantation into the postcommissural putamen in Parkinson’s disease.
38: 379–388, 1995.
Remy P, Samson Y, Hantraye P, Fontaine A, Defer G, Mangin JF et al. Clinical correlates of [18F]fluorodopa uptake in five grafted parkinsonian patients.
38: 580–588, 1995.
Defer GL, Geny C, Ricolfi F, Fenelon G, Monfort JC, Remy P et al. Long-term outcome of unilaterally transplanted parkinsonian patients. I. Clinical approach.
119: 41–50, 1996.
Wenning GK, Odin P, Morrish P, Rehncrona S, Widner H, Brundin P et al. Short- and long-term survival and function of unilateral intrastriatal dopaminergic grafts in Parkinson’s disease.
42: 95–107, 1997.
Hagell P, Schrag A, Piccini P, Jahanshahi M, Brown R, Rehncrona S et al. Sequential bilateral transplantation in Parkinson’s disease: effects of the second graft.
122: 1121–1132, 1999.
Hauser RA, Freeman TB, Snow BJ, Nauert M, Gauger L, Kordower JH et al. Long-term evaluation of bilateral fetal nigral transplantation in Parkinson disease.
56: 179–187, 1999.
Brundin P, Pogarell O, Hagell P, Piccini P, Widner H, Schrag A et al. Bilateral caudate and putamen grafts of embryonic mesencephalic tissue treated with lazaroids in Parkinson’s disease.
123: 1380–1390, 2000.
Mendez I, Dagher A, Hong M, Hebb A, Gaudet P, Law A et al. Enhancement of survival of stored dopaminergic cells and promotion of graft survival by exposure of human fetal nigral tissue to glial cell line-derived neurotrophic factor in patients with Parkinson’s disease. Report of two cases and technical considerations.
92: 863–869, 2000.
Mendez I, Dagher A, Hong M, Gaudet P, Weerasinghe S, McAlister V et al. Simultaneous intrastriatal and intranigral fetal dopaminergic grafts in patients with Parkinson disease: a pilot study. Report of three cases.
96: 589–596, 2002.
Cochen V, Ribeiro MJ, Nguyen JP, Gurruchaga JM, Villafane G, Loc’h C et al. Transplantation in Parkinson’s disease: PET changes correlate with the amount of grafted tissue.
18: 928–932, 2003.
Piccini P, Brooks DJ, Bjorklund A, Gunn RN, Grasby PM, Rimoldi O et al. Dopamine release from nigral transplants visualized in vivo in a Parkinson’s patient.
2: 1137–1140, 1999.
Freed CR, Greene PE, Breeze RE, Tsai WY, DuMouchel W, Kao R et al. Transplantation of embryonic dopamine neurons for severe Parkinson’s disease.
N Engl J Med
344: 710–719, 2001.
Kordower JH, Freeman TB, Chen EY, Mufson EJ, Sanberg PR, Hauser RA et al. Fetal nigral grafts survive and mediate clinical benefit in a patient with Parkinson’s disease.
13: 383–393, 1998.
Kordower JH, Freeman TB, Snow BJ, Vingerhoets FJ, Mufson EJ, Sanberg PR et al. Neuropathological evidence of graft survival and striatal reinnervation after the transplantation of fetal mesencephalic tissue in a patient with Parkinson’s disease.
N Engl J Med
332: 1118–1124, 1995.
Kordower JH, Rosenstein JM, Collier TJ, Burke MA, Chen EY, Li JM et al. Functional fetal nigral grafts in a patient with Parkinson’s disease: chemoanatomic, ultrastructural, and metabolic studies.
J Comp Neurol
370: 203–230, 1996.
Hagell P, Brundin P. Cell survival and clinical outcome following intrastriatal transplantation in Parkinson disease.
J Neuropathol Exp Neurol
60: 741–752, 2001.
Olanow CW, Goetz CG, Kordower JH, Stoessl AJ, Sossi V, Brin MF et al. A double-blind controlled trial of bilateral fetal nigral transplantation in Parkinson’s disease.
54: 403–414, 2003.
Playford ED, Jenkins IH, Passingham RE, Nutt J, Frackowiak RS, Brooks DJ. Impaired mesial frontal and putamen activation in Parkinson’s disease: a positron emission tomography study.
32: 151–161, 1992.
Piccini P, Lindvall O, Bjorklund A, Brundin P, Hagell P, Ceravolo R et al. Delayed recovery of movement-related cortical function in Parkinson’s disease after striatal dopaminergic grafts.
48: 689–695, 2000.
Cenci MA, Hagell P. Dyskinesias and neural grafting in Parkinson’s disease. In: Restorative therapies in Parkinson’s disease (Olanow CW, Brundin P, eds). New York: Kluwer Academic/Plenum Publishers (in press).
Hagell P, Piccini P, Bjorklund A, Brundin P, Rehncrona S, Widner H et al. Dyskinesias following neural transplantation in Parkinson’s disease.
5: 627–628, 2002.
Ma Y, Feigin A, Dhawan V, Fukuda M, Shi Q, Greene P et al. Dyskinesia after fetal cell transplantation for parkinsonism: a PET study.
52: 628–634, 2002.
Lindvall O, Hagell P. Clinical observations after neural transplantation in Parkinson’s disease.
Prog Brain Res
127: 299–320, 2000.
Vitek JL. Deep brain stimulation for Parkinson’s disease. A critical re-evaluation of STN versus GPi DBS.
Stereotact Funct Neurosurg
78: 119–131, 2002.
Braak H, Braak E. Pathoanatomy of Parkinson’s disease.
]: II3-II10, 2000.
Perl DP, Olanow CW, Calne D. Alzheimer’s disease and Parkinson’s disease: distinct entities or extremes of a spectrum of neurodegeneration?
44: S19-S31, 1998.
Agid Y, Javoy-Agid F, Ruberg M. Biochemistry of neurotransmitter in PD. In: Movement disorders 2 (Marsden CD, Fahn S, eds), pp 166–230. London: Butterworth, 1987.
Sortwell CE, Camargo MD, Pitzer MR, Gyawali S, Collier TJ. Diminished survival of mesencephalic dopamine neurons grafted into aged hosts occurs during the immediate postgrafting interval.
169: 23–29, 2001.
Doucet G, Brundin P, Descarries L, Bjorklund A. Effect of prior dopamine denervation on survival and fiber outgrowth from intrastriatal fetal mesencephalic grafts.
Eur J Neurosci
2: 279–290, 1990.
Kirik D, Winkler C, Bjorklund A. Growth and functional efficacy of intrastriatal nigral transplants depend on the extent of nigrostriatal degeneration.
21: 2889–2896, 2001.
Yurek DM, Fletcher-Turner A. Temporal changes in the neurotrophic environment of the denervated striatum as determined by the survival and outgrowth of grafted fetal dopamine neurons.
931: 126–134, 2002.
Carvey PM, Lin DH, Faselis CJ, Notermann JK, Ling ZD. Loss of striatal DA innervation increases striatal trophic activity directed at DA neurons in culture.
140: 184–197, 1996.
Ling ZD, Collier TJ, Sortwell CE, Lipton JW, Vu TQ, Robie HC et al. Striatal trophic activity is reduced in the aged rat brain.
856: 301–309, 2000.
Yurek DM, Fletcher-Turner A. Lesion-induced increase of BDNF is greater in the striatum of young versus old rat brain.
161: 392–396, 2000.
Zhou J, Pliego-Rivero B, Bradford HF, Stern GM. The BDNF content of postnatal and adult rat brain: the effects of 6-hydroxy-dopamine lesions in adult brain.
Dev Brain Res
97: 297–303, 1996.
Yurek DM, Fletcher-Turner A. Differential expression of GDNF, BDNF, and NT-3 in the aging nigrostriatal system following a neurotoxic lesion.
891: 228–235, 2001.
Björklund A, Stenevi U, Schmidt RH, Dunnett SB, Gage FH. Intracerebral grafting of neuronal cell suspensions.
Acta Physiol Scand Suppl
522: 1–48, 1983.
Dunnett SB, Whishaw IQ, Rogers DC, Jones GH. Dopamine-rich grafts ameliorate whole body motor asymmetry and sensory neglect but not independent limb use in rats with 6-hydroxydopamine lesions.
415: 63–78, 1987.
Mandel RJ, Brundin P, Bjorklund A. The importance of graft placement and task complexity for transplant-induced recovery of simple and complex sensorimotor deficits in dopamine denervated rats.
Eur J Neurosci
2: 888–894, 1990.
Annett LE, Torres EM, Ridley RM, Baker HF, Dunnett SB. A comparison of the behavioural effects of embryonic nigral grafts in the caudate nucleus and in the putamen of marmosets with unilateral 6-OHDA lesions.
Exp Brain Res
103: 355–371, 1995.
Dunnett SB, Robbins TW. The functional role of mesotelencephalic dopamine systems.
Biol Rev Camb Philos Soc
67: 491–518, 1992.
Sloan DJ, Baker BJ, Puklavec M, Charlton HM. The effect of site of transplantation and histocompatibility differences on the survival of neural tissue transplanted to the CNS of defined inbred rat strains.
Prog Brain Res
82: 141–152, 1990.
Baker-Cairns BJ, Sloan DJ, Broadwell RD, Puklavec M, Charlton HM. Contributions of donor and host blood vessels in CNS allografts.
142: 36–46, 1996.
Brundin P, Barbin G, Strecker RE, Isacson O, Prochiantz A, Bjorklund A. Survival and function of dissociated rat dopamine neurones grafted at different developmental stages or after being cultured in vitro.
467: 233–243, 1988.
Schultzberg M, Dunnett SB, Bjorklund A, Stenevi U, Hokfelt T, Dockray GJ et al. Dopamine and cholecystokinin immunoreactive neurons in mesencephalic grafts reinnervating the neostriatum: evidence for selective growth regulation.
12: 17–32, 1984.
Haque NS, LeBlanc CJ, Isacson O. Differential dissection of the rat E16 ventral mesencephalon and survival and reinnervation of the 6-OHDA-lesioned striatum by a subset of aldehyde dehydrogenase-positive TH neurons.
6: 239–248, 1997.
Isacson O, Björklund LM, Schumacher JM. Toward full restoration of synaptic and terminal function of the dopaminergic system in Parkinson’s disease by stem cells.
53: S135-S146, 2003.
Hudson JL, Hoffman A, Stromberg I, Hoffer BJ, Moorhead JW. Allogeneic grafts of fetal dopamine neurons: behavioral indices of immunological interactions.
171: 32–36, 1994.
Shinoda M, Hudson JL, Stromberg I, Hoffer BJ, Moorhead JW, Olson L. Allogeneic grafts of fetal dopamine neurons: immunological reactions following active and adoptive immunizations.
680: 180–195, 1995.
Shinoda M, Hudson JL, Stromberg I, Hoffer BJ, Moorhead JW, Olson L. Microglial cell responses to fetal ventral mesencephalic tissue grafting and to active and adoptive immunizations.
141: 173–180, 1996.
Duan WM, Widner H, Bjorklund A, Brundin P. Sequential intrastriatal grafting of allogeneic embryonic dopamine-rich neuronal tissue in adult rats: will the second graft be rejected?
57: 261–274, 1993.
Barker RA. Repairing the brain in Parkinson’s disease: where next?
17: 233–241, 2002.
Schumacher JM, Ellias SA, Palmer EP, Kott HS, Dinsmore J, Dempsey PK et al. Transplantation of embryonic porcine mesencephalic tissue in patients with PD.
54: 1042–1050, 2000.
Watts RL, Freeman TB, Hauser RA, Bakay RA, Ellias SA, Stoessl AJ et al. A double-blind, randomized, controlled, multicenter clinical trial of the safety and efficacy of stereotaxic intrastriatal implantation of fetal porcine ventral mesencephalic tissue (Neuro-cell™-PD) vs imitation surgery in patients with Parkinson’s disease (PD).
Parkinsonism Relat Disord 7[Suppl]: S87, 2001.
Lindvall O, Kokaia Z, Martinez-Serrano A. Stem cell therapy for human neurodegenerative disorders—how to make it work.
10[Suppl]: S42-S50, 2004.
Björklund LM, Sanchez-Pernaute R, Chung S, Andersson T, Chen IY, McNaught KS et al. Embryonic stem cells develop into functional dopaminergic neurons after transplantation in a Parkinson rat model.
Proc Natl Acad Sci USA
99: 2344–2349, 2002.
Kim JH, Auerbach JM, Rodriguez-Gomez JA, Velasco I, Gavin D, Lumelsky N et al. Dopamine neurons derived from embryonic stem cells function in an animal model of Parkinson’s disease.
418: 50–56, 2002.
Erdo F, Buhrle C, Blunk J, Hoehn M, Xia Y, Fleischmann B et al. Host-dependent tumorigenesis of embryonic stem cell transplantation in experimental stroke.
J Cereb Blood Flow Metab
23: 780–785, 2003.
Steece-Collier K, Collier TJ, Danielson PD, Kurlan R, Yurek DM, Sladek JR Jr. Embryonic mesencephalic grafts increase levodopa-induced forelimb hyperkinesia in parkinsonian rats.
18: 1442–1454, 2003.
PubMed CrossRef Copyright information
© The American Society for Experimental NeuroTherapeutics, Inc 2004